Clinical trials: Hepatic Chemotherapy
Liver Cancer (Primary and Metastatic)
A Study of Combination Therapy in Patients With Resectable Liver Cancer
This is a prospective, single-arm clinical study designed to evaluate the efficacy and safety of an initial combination treatment strategy followed by surgery in patients with cancer.
- Trial name
- Archer (NCT07684040)
- Testing
- Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Plus Rivoceranib
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Colorectal Cancer Metastatic to Liver, Intrahepatic Cholangiocarcinoma
Infusion System for Hepatic Cancer
This is a single-site, open-label continued access study/treatment protocol under a treatment IDE. In addition to treating patients, the primary objective of this study is to assess the safety of using the Medtronic SynchroMed II…
- Trial name
- NCT04684862
- Testing
- Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ronald DeMatteo, M.D.
Hepatic Impairment, Healthy Volunteers
A Study of TAK-279 in Adults With or Without Liver Damage
The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to participants without liver problems.
- Trial name
- NCT05976321
- Testing
- TAK-279
- Where
- 4 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver.
- Trial name
- NCT07504471
- Testing
- pH-NASOX-Immune Group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
HCC
A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
Major Objectives To evaluate the efficacy of HAIC combined with Iparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) plus bevacizumab as a conversion therapy in patients with potentially…
- Trial name
- NCT07119931
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma
Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC) refractory to transarterial…
- Trial name
- NCT03722498
- Testing
- HAIC of FOLFOX, Sorafenib
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Biliary Tract Cancer
HAIC Rechallenge in Biliary Tract Cancer and Colorectal Cancer Liver Metastases: Efficacy and Safety in Patients Resistant to Previous Systemic Chemotherapy
Plain Language Summary This study uses hepatic arterial infusion chemotherapy (HAIC) rechallenge for patients with biliary tract cancer or colorectal cancer liver metastases whose disease has progressed after previous systemic…
- Trial name
- NCT07830147
- Testing
- Hepatic Arterial Infusion Chemotherapy (HAIC) Rechallenge
- Where
- China
- Volunteers
- 72 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma (HCC)
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
This is a multicenter，retrospective study to explore the effectiveness and safety of Atezo/Bev plus hepatic artery infusion chemotherapy (HAIC) among adult patients with high-risk HCC in real-world clinical practice in China.
- Trial name
- NCT07272265
- Testing
- Atezolizumab & Bevacizumab, FOLFOX-HAIC
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cryosurgery kills cancer cells by freezing them.
- Trial name
- NCT00008294
- Testing
- FOLFOX regimen, dexamethasone, floxuridine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer, Hepatic Metastases
Targeted Delivery of Chemotherapy With Ultrasound and Microbublles
The oscillations of ultrasound (US) contrast agent microbubbles under their activation by US waves engender a modulation of the permeability of biological barriers amplifying hence the extravasation of drugs and/or fluorescent…
- Trial name
- SONCHIMIO (NCT03458975)
- Testing
- MRI, Perfusion CT scan, Contrast enhanced ultrasound
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Tours
Colorectal Neoplasms
Trial of Preoperative Hepatic and Regional Arterial Chemotherapy (PHRAC) to Prevent Postoperative Liver Metastasis of Colorectal Cancer
The purpose of this study is to investigate whether preoperative hepatic and regional arterial chemotherapy are able to prevent liver metastasis and improve overall survival in patients receiving curative colorectal cancer…
- Trial name
- PHRAC (NCT00643877)
- Testing
- Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR, surgery
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Fudan University
Colorectal Cancer, Metastatic Cancer
Radiofrequency Ablation Followed By Hepatic Artery Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Radiofrequency ablation may be able to shrink or destroy cancer cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00004142
- Testing
- Floxuridine, Fluorouracil (5-FU), Conventional surgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Hepatic Chemotherapy
HAIC Compared With TACE in Huge Hepatocellular Carcinoma
This study intends to compare the efficacy of transcatheter arterial chemical embolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) for patients with intermediate-advanced huge hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer
- Trial name
- NCT06641713
- Testing
- TACE, HAIC
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma (HCC)
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
This is a single-center, single-arm, prospective trial to explore the efficacy and safety of Icaritin Soft Capsules combined with postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC) with Modified Folinic acid…
- Trial name
- NCT07337460
- Testing
- Icaritin Soft Capsules and mFOLFOX ：Oxaliplatin,leucovorin calcium,5-fluorouracil
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Liver Cancer
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
- Trial name
- NCT07587034
- Testing
- HTAC, HAC, TAC
- Volunteers
- 315 people
- Sponsor
- Shanghai Zhongshan Hospital
Metastatic Colorectal Cancer
Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases
Bevacizumab, an anti-angiogenic agent, plus fluorouracil based chemotherapy is considered a new standard for the treatment of metastatic colorectal cancer.
- Trial name
- NCT00489697
- Testing
- real-time contrast-enhanced ultrasound imaging (CEUS)
- Where
- 12 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Tours
Colorectal Cancer
Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases
The main objective is to compare resection rates (R0 or R1) for hepatic metastases in the experimental arm (tri chemotherapy plus targeted therapy) versus the control arm (bi chemotherapy plus targeted therapy); in both arms the…
- Trial name
- NCT01442935
- Testing
- Oxaliplatin, Folinic Acid, 5-FU
- Where
- France
- Volunteers
- 256 people
- Sponsor
- UNICANCER
Locally Advanced Hepatocellular Carcinoma
Natural Killer (NK) Cell Therapy in Locally Advanced HCC
This Phase 2a trial will evaluate the safety and efficacy of NK cell therapy combined with the hepatic artery infusion chemotherapy (HAIC) in patients with intermediate and/or locally advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05040438
- Testing
- Vax-NK/HCC
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Vaxcell Bio, Co., Ltd.
Advanced Hepatocellular Carcinoma, Carcinoma
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
- Conditions
- Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms
- Trial name
- NCT01214343
- Testing
- Sorafenib with Low-dose FP, Sorafenib
- Where
- 30 sites in Japan
- Volunteers
- 190 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Carcinoma, Carcinoma, Hepatocellular
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
This is an open-label，multi-center ，non-randomized ，single arm exploratory study . This clinical study is an investigator-initiated clinical trial（IIT ）.
- Conditions
- Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Digestive System Neoplasms
- Trial name
- NCT04962958
- Testing
- Hepatic arterial infusion chemotherapy, Folfox Protocol, Donafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University